Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Phase 4
730
about 3.6 years
6+
59 sites in AL, AZ, CA +29
What this study is about
This trial is testing whether a single aminoglycoside antibiotic, combined with a beta-lactam antibiotic, is as effective as two different antibiotics (tobramycin and a beta-lactam) in treating pulmonary exacerbations in people with cystic fibrosis. The goal is to determine if using one type of antibiotic provides the same improvement in lung function and symptoms compared to using two types.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Aminoglycoside
- 2.Take Beta-lactam antibiotic
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
antibiotic
Primary: Absolute Change in FEV1 % Predicted at Week 4 in Aminoglycoside (AG) Study, Incidence of Adverse Events (AEs) in Aminoglycoside (AG) Study Intervention Arms
Respiratory